Lumicell developed the technology to enable physicians to detect residual cancer in the breast cavity after surgery.

Lumicell today announced it received FDA approval for its LumiSystem direct visualization system for breast cancer removal.

The Food and Drug Administration approved Tivdak for metastatic cervical cancer that progressed on or after chemotherapy. The Food and Drug Administration (FDA) approved Tivdak (tisotumab vedotin-tftv ...

The U.S. Food and Drug Administration (FDA ... available for BCG-unresponsive non–muscle-invasive bladder cancer. "The FDA approval of N-803 heralds a new era in the management of BCG ...

The recent FDA approval of Hercessi expands access to a treatment previously burdened by high costs. Hercessi joins the 5 ...

Approval was supported by data from a randomized, intra-patient controlled trial, which included patients with confirmed invasive breast cancer, ductal carcinoma in situ, or both. The Food and ...

The approval marks the sixth for a biosimilar referencing Herceptin (trastuzumab) for the treatment of HER2-positive breast ...

The drug itself is designed to mimic a type of cell that causes the immune system to churn out so-called memory killer T cells that recognize and attack bladder cancer cells. Last May, the FDA had ...

A California-based immunotherapy company with local operations received good news this week that the U.S. Food and Drug Administration has approved its bladder cancer treatment drug. ImmunityBio ...

The FDA has approved a first-in-class bladder cancer drug. Anktiva (interleukin (IL)-15 superagonist nogapendekin alfa inbakicept-pmln) administered with bacillus Calmette-Guérin was approved for ...

Hercessi marks Accord BioPharma’s first biosimilar to be approved in the United States, with multiple indications for ...